CA3044219A1 - Transdermal delivery of large agents - Google Patents
Transdermal delivery of large agents Download PDFInfo
- Publication number
- CA3044219A1 CA3044219A1 CA3044219A CA3044219A CA3044219A1 CA 3044219 A1 CA3044219 A1 CA 3044219A1 CA 3044219 A CA3044219 A CA 3044219A CA 3044219 A CA3044219 A CA 3044219A CA 3044219 A1 CA3044219 A1 CA 3044219A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- skin
- composition
- antibody
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037317 transdermal delivery Effects 0.000 title abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 498
- 238000000034 method Methods 0.000 claims abstract description 98
- 239000003795 chemical substances by application Substances 0.000 claims description 399
- 210000003491 skin Anatomy 0.000 claims description 289
- 239000007908 nanoemulsion Substances 0.000 claims description 205
- 108030001720 Bontoxilysin Proteins 0.000 claims description 177
- 229940053031 botulinum toxin Drugs 0.000 claims description 171
- 238000011282 treatment Methods 0.000 claims description 127
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 94
- 239000006071 cream Substances 0.000 claims description 90
- 239000006210 lotion Substances 0.000 claims description 84
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 84
- 239000004907 Macro-emulsion Substances 0.000 claims description 77
- 230000000699 topical effect Effects 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 69
- 239000000839 emulsion Substances 0.000 claims description 66
- 230000037303 wrinkles Effects 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 59
- 208000035475 disorder Diseases 0.000 claims description 54
- 239000013543 active substance Substances 0.000 claims description 53
- 239000003961 penetration enhancing agent Substances 0.000 claims description 52
- 230000003750 conditioning effect Effects 0.000 claims description 48
- 230000002500 effect on skin Effects 0.000 claims description 42
- 230000027455 binding Effects 0.000 claims description 40
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 33
- 210000000434 stratum corneum Anatomy 0.000 claims description 33
- 230000035900 sweating Effects 0.000 claims description 26
- 239000000499 gel Substances 0.000 claims description 21
- 239000002674 ointment Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 16
- 210000004207 dermis Anatomy 0.000 claims description 15
- 239000000865 liniment Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 210000003205 muscle Anatomy 0.000 claims description 14
- 230000001815 facial effect Effects 0.000 claims description 13
- 239000006196 drop Substances 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 11
- 230000009885 systemic effect Effects 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 206010025135 lupus erythematosus Diseases 0.000 claims description 8
- 231100000344 non-irritating Toxicity 0.000 claims description 8
- 210000003780 hair follicle Anatomy 0.000 claims description 7
- 230000037315 hyperhidrosis Effects 0.000 claims description 7
- 208000035985 Body Odor Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 229940040145 liniment Drugs 0.000 claims description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 5
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 108010008165 Etanercept Proteins 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 210000000106 sweat gland Anatomy 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 206010055000 Bromhidrosis Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 206010062575 Muscle contracture Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 229940035674 anesthetics Drugs 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 239000000560 biocompatible material Substances 0.000 claims description 3
- 208000015318 chromhidrosis Diseases 0.000 claims description 3
- 230000037371 chromhidrosis Effects 0.000 claims description 3
- 208000006111 contracture Diseases 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 210000001732 sebaceous gland Anatomy 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000014094 Dystonic disease Diseases 0.000 claims description 2
- 206010063006 Facial spasm Diseases 0.000 claims description 2
- 208000004095 Hemifacial Spasm Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 208000021710 Hyperpigmentation disease Diseases 0.000 claims description 2
- 208000026748 Hypopigmentation disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 241000223503 Platysma Species 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 208000004350 Strabismus Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 229960002874 briakinumab Drugs 0.000 claims description 2
- 229960003735 brodalumab Drugs 0.000 claims description 2
- 229960003115 certolizumab pegol Drugs 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 230000008921 facial expression Effects 0.000 claims description 2
- 229950010512 fezakinumab Drugs 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 229950010864 guselkumab Drugs 0.000 claims description 2
- 230000001660 hyperkinetic effect Effects 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 229960004540 secukinumab Drugs 0.000 claims description 2
- 229950003804 siplizumab Drugs 0.000 claims description 2
- 208000018198 spasticity Diseases 0.000 claims description 2
- 229960003824 ustekinumab Drugs 0.000 claims description 2
- 229950009002 zanolimumab Drugs 0.000 claims description 2
- 238000011269 treatment regimen Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010011659 Cutaneous amyloidosis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000017 cortisol group Chemical group 0.000 claims 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims 1
- 125000002345 steroid group Chemical group 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 description 121
- 238000005516 engineering process Methods 0.000 description 115
- 206010040954 Skin wrinkling Diseases 0.000 description 86
- 241000282414 Homo sapiens Species 0.000 description 47
- 229920001184 polypeptide Polymers 0.000 description 47
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 46
- 238000012384 transportation and delivery Methods 0.000 description 45
- 239000010410 layer Substances 0.000 description 44
- 210000004243 sweat Anatomy 0.000 description 44
- 238000012360 testing method Methods 0.000 description 43
- 239000003814 drug Substances 0.000 description 41
- 201000010099 disease Diseases 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 239000012634 fragment Substances 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- -1 exfoliants Substances 0.000 description 30
- 239000000463 material Substances 0.000 description 27
- 230000001225 therapeutic effect Effects 0.000 description 27
- 239000000427 antigen Substances 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 239000004094 surface-active agent Substances 0.000 description 26
- 238000011200 topical administration Methods 0.000 description 26
- 229940124597 therapeutic agent Drugs 0.000 description 25
- 239000000126 substance Substances 0.000 description 24
- 239000000546 pharmaceutical excipient Substances 0.000 description 22
- 239000003921 oil Substances 0.000 description 21
- 150000003384 small molecules Chemical class 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 239000012049 topical pharmaceutical composition Substances 0.000 description 21
- 239000007788 liquid Substances 0.000 description 20
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 20
- 239000002105 nanoparticle Substances 0.000 description 19
- 230000035515 penetration Effects 0.000 description 19
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 17
- 230000009467 reduction Effects 0.000 description 17
- 239000002612 dispersion medium Substances 0.000 description 16
- 239000011630 iodine Substances 0.000 description 16
- 229910052740 iodine Inorganic materials 0.000 description 16
- 210000004907 gland Anatomy 0.000 description 15
- 239000011148 porous material Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000006378 damage Effects 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 150000002605 large molecules Chemical class 0.000 description 13
- 229920002521 macromolecule Polymers 0.000 description 13
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000012466 permeate Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 230000001143 conditioned effect Effects 0.000 description 10
- 210000002615 epidermis Anatomy 0.000 description 10
- 230000003631 expected effect Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 10
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 10
- 229960003415 propylparaben Drugs 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000012266 salt solution Substances 0.000 description 10
- 230000037331 wrinkle reduction Effects 0.000 description 10
- 229920002261 Corn starch Polymers 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 206010033799 Paralysis Diseases 0.000 description 9
- 238000005299 abrasion Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 208000030961 allergic reaction Diseases 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 239000008120 corn starch Substances 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 231100000021 irritant Toxicity 0.000 description 9
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 9
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 9
- 229960002216 methylparaben Drugs 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 239000002085 irritant Substances 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 238000013271 transdermal drug delivery Methods 0.000 description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 6
- 241000193155 Clostridium botulinum Species 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
- 229940068968 polysorbate 80 Drugs 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 239000001022 rhodamine dye Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000013043 chemical agent Substances 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000008387 emulsifying waxe Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 239000003871 white petrolatum Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 101710138657 Neurotoxin Proteins 0.000 description 4
- 240000007643 Phytolacca americana Species 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 235000019800 disodium phosphate Nutrition 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002581 neurotoxin Substances 0.000 description 4
- 231100000618 neurotoxin Toxicity 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000011285 therapeutic regimen Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 3
- 239000003082 abrasive agent Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000011078 sorbitan tristearate Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940095694 transdermal product Drugs 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 208000003508 Botulism Diseases 0.000 description 2
- 241000498849 Chlamydiales Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 231100000858 damage to nervous tissue Toxicity 0.000 description 2
- 239000008380 degradant Substances 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 108010024001 incobotulinumtoxinA Proteins 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 238000011170 pharmaceutical development Methods 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 150000004040 pyrrolidinones Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- YXIBXUGCDCJBPD-JYJNAYRXSA-N (2s)-2,6-diamino-n-[2-[[(2s)-1-[[(2s)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]hexanamide Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 YXIBXUGCDCJBPD-JYJNAYRXSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010069803 Injury associated with device Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101100450263 Mus musculus Hadh gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000022034 Penile disease Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000606726 Rickettsia typhi Species 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000036617 axillary hyperhidrosis Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 108010069022 botulinum toxin type D Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 238000000375 direct analysis in real time Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000012063 dual-affinity re-targeting Methods 0.000 description 1
- 229940098753 dysport Drugs 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000194 fatty acid Chemical class 0.000 description 1
- 229930195729 fatty acid Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 238000001053 micromoulding Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229950008885 polyglycolic acid Drugs 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940018272 xeomin Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424937P | 2016-11-21 | 2016-11-21 | |
| US62/424,937 | 2016-11-21 | ||
| PCT/US2017/053333 WO2018093465A1 (en) | 2016-11-21 | 2017-09-25 | Transdermal delivery of large agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3044219A1 true CA3044219A1 (en) | 2018-05-24 |
Family
ID=60037726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3044219A Pending CA3044219A1 (en) | 2016-11-21 | 2017-09-25 | Transdermal delivery of large agents |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11311496B2 (enExample) |
| EP (1) | EP3541358A1 (enExample) |
| JP (3) | JP2019535829A (enExample) |
| KR (1) | KR102487144B1 (enExample) |
| CN (2) | CN117731591A (enExample) |
| AU (1) | AU2017360346B2 (enExample) |
| BR (1) | BR112019010131A2 (enExample) |
| CA (1) | CA3044219A1 (enExample) |
| IL (1) | IL266733A (enExample) |
| MX (2) | MX2019005833A (enExample) |
| WO (1) | WO2018093465A1 (enExample) |
| ZA (1) | ZA201903467B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| BR112019025402A2 (pt) * | 2017-05-31 | 2020-06-23 | Allergan, Inc. | Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso |
| US20210275691A1 (en) * | 2018-05-30 | 2021-09-09 | Allergan, Inc. | Screening assay to assess topical delivery of biological therapeutic agents |
| CN113286579A (zh) * | 2018-08-23 | 2021-08-20 | 埃里克·F·伯恩斯坦 | 应用抗vegf化合物和使用这类化合物治疗皮肤病的系统、装置和方法 |
| AU2019391791A1 (en) * | 2018-12-03 | 2021-06-03 | Eirion Therapeutics, Inc. | Improved delivery of large agents |
| JP2022533113A (ja) * | 2019-05-14 | 2022-07-21 | エイリオン セラピューティクス， インコーポレイテッド | ピーク効果の遅延および／または応答持続時間の延長 |
| WO2022182738A1 (en) * | 2021-02-23 | 2022-09-01 | Nanomed Skincare, Inc. | Method of administering a dual therapeutic and cosmetic agent |
| US20240261552A1 (en) * | 2021-05-21 | 2024-08-08 | Veradermics Incorporated | Microneedle patch for immunostimulatory drug delivery |
| US20240390660A1 (en) * | 2021-09-29 | 2024-11-28 | University Of Iowa Research Foundation | Apparatus, systems and methods for transdermal drug delivery, permeability enhancement and augmentation |
| CN116925213B (zh) * | 2023-09-12 | 2024-03-15 | 中国人民解放军军事科学院军事医学研究院 | 一种中和a型肉毒毒素的纳米抗体 |
Family Cites Families (358)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US3725540A (en) | 1970-07-30 | 1973-04-03 | Procter & Gamble | Color and odor stabilized dry aerosol antiperspirant |
| US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
| CH587021A5 (enExample) | 1974-06-07 | 1977-04-29 | Nestle Sa | |
| US4152170A (en) | 1975-06-18 | 1979-05-01 | Sumitomo Chemical Company, Ltd. | Cross-linked pullulan |
| JPS541064Y2 (enExample) | 1975-09-18 | 1979-01-19 | ||
| US4172149A (en) | 1978-01-30 | 1979-10-23 | Westwood Pharmaceuticals, Inc. | Method for treating living skin exhibiting excessive sebum secretion |
| DE2929425A1 (de) | 1979-07-20 | 1981-02-12 | Lothar Kling | Vorrichtung fuer injektionsspritzen zur intramuskulaeren und subentanen injektion |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4533254A (en) | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
| US4908154A (en) | 1981-04-17 | 1990-03-13 | Biotechnology Development Corporation | Method of forming a microemulsion |
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| JPH07116268B2 (ja) | 1984-01-09 | 1995-12-13 | 大西 靖彦 | デキストランの陰イオン性部分置換体とオレフィン化合物との共重合体の製法 |
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| IL88076A (en) | 1987-10-28 | 1993-01-14 | Nippon Shinyaku Co Ltd | Fat emulsions as drug carriers |
| US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
| JPH0798740B2 (ja) | 1987-10-28 | 1995-10-25 | 日本新薬株式会社 | 薬物担体 |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| CH677886A5 (enExample) | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
| FR2659554B1 (fr) | 1990-03-16 | 1994-09-30 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
| US5401243A (en) | 1990-08-21 | 1995-03-28 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| JP3765579B2 (ja) | 1990-08-24 | 2006-04-12 | イーデーエーアー アーゲー | 作用物質投与用超微小滴状調剤 |
| JPH04202122A (ja) | 1990-11-28 | 1992-07-22 | Procter & Gamble Co:The | ジケトン脱臭組成物及び脱臭方法 |
| JPH04198122A (ja) | 1990-11-28 | 1992-07-17 | Procter & Gamble Co:The | チオールヘテロ環脱臭組成物及び脱臭方法 |
| JPH04198123A (ja) | 1990-11-28 | 1992-07-17 | Procter & Gamble Co:The | アミン脱臭組成物及び脱臭方法 |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US5652274A (en) | 1991-03-01 | 1997-07-29 | Martin; Alain | Therapeutic-wound healing compositions and methods for preparing and using same |
| AU664827B2 (en) | 1991-05-03 | 1995-12-07 | Raisio Benecol Ltd. | A substance for lowering high cholesterol level in serum and a method for preparing the same |
| JPH04351623A (ja) | 1991-05-28 | 1992-12-07 | Nippon Kayaku Co Ltd | 新規ブロック共重合体及びその製造方法 |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| US7384918B2 (en) | 1991-09-24 | 2008-06-10 | Allergan, Inc. | Botulinum toxin for treating muscle contracture |
| US6939852B2 (en) | 1991-09-24 | 2005-09-06 | Allergan, Inc. | Methods and compositions for the treatment of cerebral palsy |
| US5613952A (en) | 1991-12-23 | 1997-03-25 | Syringe Develpoment Partners | Safety syringe |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| IL101387A (en) | 1992-03-26 | 1999-11-30 | Pharmos Ltd | Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| EP0571677A1 (en) | 1992-05-29 | 1993-12-01 | Unilever Plc | Aqueous parfume oil microemulsions |
| EP0572080B1 (en) | 1992-05-29 | 1995-11-15 | Quest International B.V. | Aqueous perfume oil microemulsions |
| CA2138020C (en) * | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| CA2091152C (en) | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
| US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| US5470577A (en) | 1993-07-07 | 1995-11-28 | Trustees Of Boston University | Stimulation of tanning by DNA fragments or single-stranded DNA |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US8187612B2 (en) | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| JPH07285863A (ja) | 1994-02-25 | 1995-10-31 | Takeda Chem Ind Ltd | 注射剤組成物およびその製造方法 |
| HUT74735A (en) | 1994-02-25 | 1997-02-28 | Takeda Chemical Industries Ltd | Injectable emulsion composition containing antifungal triazole derivatives and process for producing it |
| JP2930421B2 (ja) | 1994-02-28 | 1999-08-03 | メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物、その製造方法及びその使用方法 |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| ES2078190B1 (es) | 1994-05-20 | 1996-08-01 | Cusi Lab | Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico. |
| US5843334A (en) | 1994-06-20 | 1998-12-01 | Nippon Shinyaku Co., Ltd. | Method of producing emulsions and an emulsification apparatus |
| US5672358A (en) | 1994-06-21 | 1997-09-30 | Ascent Pharmaceuticals, Inc. | Controlled release aqueous emulsion |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US20020048596A1 (en) | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
| US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| FR2730932B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DE69627963T2 (de) | 1995-06-06 | 2004-03-04 | Pearce, L. Bruce, Cambridge | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
| US5660858A (en) | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
| JPH10114648A (ja) | 1996-10-11 | 1998-05-06 | Kao Corp | 皮膚外用組成物 |
| WO1998020834A2 (en) | 1996-11-12 | 1998-05-22 | Tamarkin Pharmaceutical Innovation Ltd | Method for treatment of dermatological disorders |
| FR2755854B1 (fr) | 1996-11-15 | 1998-12-24 | Oreal | Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations |
| EP0952762B1 (en) | 1996-12-19 | 2011-10-12 | Ibiden Co, Ltd. | Printed wiring board and method for manufacturing the same |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6461596B1 (en) | 1997-02-18 | 2002-10-08 | Andrea Taylor | Composition and method for promoting hair growth |
| FR2760970B1 (fr) | 1997-03-18 | 2000-03-10 | Oreal | Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations |
| US5994414A (en) | 1997-04-28 | 1999-11-30 | Avon Products, Inc. | Water-thin emulsion formed by high pressure homogenization process |
| GB9708066D0 (en) | 1997-04-22 | 1997-06-11 | Woolcombers Group Plc | Compositions and their use |
| US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
| DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| ES2218685T3 (es) | 1997-06-13 | 2004-11-16 | Nanodel Technologies Gmbh | Sistema para direccion de farmaco, procedimiento para su preparacion y su utilizacion. |
| CN1068524C (zh) | 1997-06-23 | 2001-07-18 | 叶庆炜 | 一种治疗顽症牛皮癣的药物 |
| CA2505933C (en) | 1997-07-15 | 2008-09-30 | Richard A. Schmidt | Use of botulinum toxin for treating urinary incontinence |
| US6007856A (en) | 1997-08-08 | 1999-12-28 | The Procter & Gamble Company | Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US5993852A (en) | 1997-08-29 | 1999-11-30 | Pharmaderm Laboratories Ltd. | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
| US6007803A (en) | 1997-09-19 | 1999-12-28 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin binding agents |
| IT1296914B1 (it) | 1997-12-01 | 1999-08-03 | Maria Rosa Gasco | Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| EP1080720A4 (en) | 1998-03-05 | 2002-06-05 | Nippon Shinyaku Co Ltd | FAT EMULSIONS FOR INHALATIVE ADMINISTRATION |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| EP0953632B1 (de) | 1998-03-30 | 2007-09-05 | Mibelle AG Cosmetics | Verwendung von Nanoemulsionen zur Bestimmung der Biokompatibilität von lipophilen Stoffen im Zellkultur-Test und dafür geeignete Nanoemulsionen |
| FI111513B (fi) | 1998-05-06 | 2003-08-15 | Raisio Benecol Oy | Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi |
| US5932562A (en) | 1998-05-26 | 1999-08-03 | Washington University | Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same |
| US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| FR2783169B1 (fr) | 1998-09-15 | 2001-11-02 | Sederma Sa | Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution) |
| US6242001B1 (en) | 1998-11-30 | 2001-06-05 | Mcneil-Ppc, Inc. | Method for producing dispersible sterol and stanol compounds |
| DE19856897A1 (de) | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| FR2787728B1 (fr) | 1998-12-23 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| AU770803B2 (en) | 1998-12-23 | 2004-03-04 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
| FR2788007B1 (fr) | 1999-01-05 | 2001-02-09 | Oreal | Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| US20030229141A1 (en) | 1999-01-08 | 2003-12-11 | Yu Ruey J. | N-acetyl cysteine and its topical use |
| WO2000041528A2 (en) | 1999-01-14 | 2000-07-20 | Amcol International Corporation | Improved controlled release compositions and method |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US20020054914A1 (en) | 1999-02-03 | 2002-05-09 | Tulin Morcol | Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| EP1100475A1 (en) | 1999-06-02 | 2001-05-23 | Medinova Medical Consulting Gmbh | Use of drug-loaded nanoparticles for the treatment of cancers |
| US6611707B1 (en) * | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| EP1189597A4 (en) | 1999-06-04 | 2008-06-18 | Pacira Pharmaceuticals Inc | COMPOSITIONS USING AN OIL CORE FOR DELAYED RELEASE HYDROPHOLE MEDICAMENTS |
| US6256533B1 (en) * | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| AU5409699A (en) | 1999-07-05 | 2001-01-22 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers |
| AU7271800A (en) | 1999-08-04 | 2001-03-05 | Idea Ag | Periodic structures comprising lipids, polyelectrolytes, and structure-inducing soluble oligovalent linkers, and biological use thereof |
| US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6429189B1 (en) | 1999-12-10 | 2002-08-06 | Botulinum Toxin Research Associates, Inc. | Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases |
| CA2395493C (en) | 1999-12-28 | 2010-06-22 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
| US6898427B1 (en) | 1999-12-29 | 2005-05-24 | Bellsouth Intellectual Property Corporation | Method of coupling portable communications device to first network by way of second network |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| FR2804015B1 (fr) | 2000-01-21 | 2005-12-23 | Oreal | Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations |
| US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| FR2805761B1 (fr) | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
| DE60138804D1 (de) | 2000-03-23 | 2009-07-09 | Basf Catalysts Llc | Verfahren zur herstellung von physiologisch aktiven substanzen enthaltenden dispersionen unter anwendung von hochdruck und hochscherkraft |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6471968B1 (en) | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
| FR2809112B1 (fr) | 2000-05-16 | 2004-05-07 | Centre Nat Rech Scient | Materiaux a base de polymeres biodegradables et son procede de preparation |
| FR2809010B1 (fr) | 2000-05-22 | 2002-07-12 | Oreal | Nanoemulsion a base de polymeres anioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| US6670322B2 (en) | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| US20020155084A1 (en) | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| FR2811561B1 (fr) | 2000-07-13 | 2003-03-21 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase |
| US20040220100A1 (en) | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| US6455058B1 (en) | 2000-09-13 | 2002-09-24 | Amitee Cosmetics, Inc. | Composition and method for hair and scalp treatment |
| CA2427858A1 (en) | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| FR2816949B1 (fr) | 2000-11-17 | 2003-11-28 | Centre Nat Rech Scient | Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes |
| US7255865B2 (en) | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
| US20020086036A1 (en) | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
| ATE374603T1 (de) | 2000-12-27 | 2007-10-15 | Ares Trading Sa | Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation |
| FR2819427B1 (fr) | 2001-01-18 | 2003-04-11 | Oreal | Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FI20010115A0 (fi) | 2001-01-18 | 2001-01-18 | Orion Corp | Menetelmä nanopartikkelien valmistamiseksi |
| US8216797B2 (en) | 2001-02-07 | 2012-07-10 | Massachusetts Institute Of Technology | Pathogen detection biosensor |
| US20030072841A1 (en) | 2001-03-19 | 2003-04-17 | The Procter & Gamble Campany | Polybutene containing chewing gum and confection |
| EP1379227A4 (en) | 2001-03-21 | 2007-12-12 | Univ Kentucky Res Found | MICROEMULSIONS AS PRECURSORS OF SOLID NANOPARTICLES |
| US20040048836A1 (en) | 2001-03-23 | 2004-03-11 | Wilmott James M | Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients |
| AU2002258644B2 (en) | 2001-03-30 | 2006-12-14 | Color Access, Inc. | Novel nanoemulsions |
| KR100463167B1 (ko) | 2001-04-13 | 2004-12-23 | 주식회사 태평양 | 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물 |
| JP2006512401A (ja) | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
| US6767341B2 (en) * | 2001-06-13 | 2004-07-27 | Abbott Laboratories | Microneedles for minimally invasive drug delivery |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| KR100566911B1 (ko) | 2001-06-25 | 2006-04-03 | 주식회사 삼양사 | 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체 |
| US7226605B2 (en) | 2001-07-27 | 2007-06-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
| US20150037402A1 (en) | 2001-08-13 | 2015-02-05 | Lipella Pharmaceuticals, Inc. | Methods and Compositions for Treating Gastric Disorders |
| WO2003015698A2 (en) | 2001-08-13 | 2003-02-27 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| DE10146647A1 (de) | 2001-09-21 | 2003-04-24 | Marc Heckmann | Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis |
| US7235230B2 (en) | 2001-10-24 | 2007-06-26 | Clariant Finance (Bvi) Limited | Leave-on compositions for personal care |
| US20030077240A1 (en) | 2001-10-24 | 2003-04-24 | Clariant International, Ltd. | Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions |
| AU2002333155A1 (en) | 2001-10-30 | 2003-05-12 | Pentapharm Ag | Dermopharmaceutically and cosmetically active oligopeptides |
| US6745211B2 (en) * | 2001-11-21 | 2004-06-01 | Ge Financial Assurance Holdings, Inc. | Method and system for verifying and correcting data records in a database |
| US20030113349A1 (en) | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
| US7763663B2 (en) | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
| US6765001B2 (en) | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
| KR100441167B1 (ko) | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | 마이크로에멀젼 예비 농축액 조성물 |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| EP1334729A1 (en) | 2002-02-07 | 2003-08-13 | Botulinum Toxin Research Associates, Inc. | Therapeutic use of non-neurotoxic clostridium botulinum toxin type C2 |
| CA2476761A1 (en) | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| US6861066B2 (en) | 2002-03-11 | 2005-03-01 | Health Plus International Inc. | Method for the delivery of a biologically active agent |
| US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| US6623780B1 (en) | 2002-03-26 | 2003-09-23 | Cargill, Inc. | Aqueous dispersible sterol product |
| US20040115159A1 (en) | 2002-03-29 | 2004-06-17 | Tadlock Charles C | Novel nanoemulsions |
| US6875438B2 (en) | 2002-04-27 | 2005-04-05 | Aventis Pharma Deutschland Gmbh | Preparations for topical administration of substances having antiandrogenic activity |
| DE60311801T2 (de) | 2002-05-02 | 2007-11-08 | PR Pharmaceuticals, Inc., Fort Collins | Zusammensetzungen aus östradiol-metaboliten mit kontrollierter freisetzung |
| JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| US7459164B2 (en) | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
| US7691394B2 (en) | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| WO2003101483A1 (en) | 2002-05-31 | 2003-12-11 | Solux Corporation | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
| JP2005531606A (ja) | 2002-06-10 | 2005-10-20 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ステロール製剤およびステロールの組合せ |
| US20050214378A1 (en) | 2002-06-11 | 2005-09-29 | Ethypharm | Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| US6996748B2 (en) | 2002-06-29 | 2006-02-07 | Intel Corporation | Handling faults associated with operation of guest software in the virtual-machine architecture |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US7824693B2 (en) | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
| AU2003270575A1 (en) | 2002-09-12 | 2004-04-30 | 3M Innovative Properties Company | Fluoroelastomers having low temperature characteristics and solvent resistance |
| EP1590034B1 (en) * | 2002-10-07 | 2014-05-14 | Biovalve Technologies, Inc. | Microneedle array patch |
| US20070292359A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US20040115727A1 (en) | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
| DE10258960A1 (de) | 2002-12-16 | 2004-07-01 | Henkel Kgaa | Nanoskalige Hydrogele gegen Falten, raue und trockene Haut |
| US7329688B2 (en) | 2002-12-17 | 2008-02-12 | Soft Gel Technologies, Inc. | Natural vitamin E compositions with superior antioxidant potency |
| MXPA05006690A (es) | 2002-12-20 | 2006-02-17 | Botulinum Toxin Res Ass Inc | Composiciones farmaceuticas de toxina botulinica mejoradas. |
| FR2849375B1 (fr) | 2002-12-30 | 2006-10-20 | Jean Noel Thorel | Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit |
| EP1587499A1 (en) | 2003-01-31 | 2005-10-26 | Elan Pharma International Limited | Nanoparticulate topiramate formulations |
| US20060165657A1 (en) | 2003-02-05 | 2006-07-27 | Paul Bernasconi | Method for delivery of cosmetic by topical application |
| US20060153876A1 (en) | 2003-02-24 | 2006-07-13 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease |
| US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
| WO2004084839A2 (en) | 2003-03-24 | 2004-10-07 | Cady Roger K | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
| US20040191330A1 (en) | 2003-03-31 | 2004-09-30 | Keefe Candace R. | Daily skin care regimen |
| WO2004087203A2 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| CA2521051C (en) | 2003-04-04 | 2012-03-20 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
| PL1651162T3 (pl) | 2003-05-20 | 2016-04-29 | Immunogen Inc | Maitansynoidy w leczeniu nowotworów |
| GB0312309D0 (en) | 2003-05-29 | 2003-07-02 | Gaslini Children S Hospital G | Targeted liposome |
| US20050079228A1 (en) | 2003-05-30 | 2005-04-14 | Ashish Jaiswal | Clear, stable topical compositions of clarithromycin and processes for their preparation |
| WO2005027872A2 (en) | 2003-06-04 | 2005-03-31 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
| US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
| EP1640017A1 (en) | 2003-06-20 | 2006-03-29 | Santen Pharmaceutical Co., Ltd. | Remedies for diseases with hypermyotonia |
| EP1720605A4 (en) | 2003-06-23 | 2007-10-24 | Transpharma Medical Ltd | TRANSDERMAL DELIVERY SYSTEM FOR COSMETIC AGENTS |
| US20050013850A1 (en) | 2003-07-15 | 2005-01-20 | Caers Jan K. | Device to assist hyperhydrosis therapy |
| AU2004263040B2 (en) | 2003-08-06 | 2010-03-11 | Eisai R&D Management Co., Ltd. | Process for producing drug ultramicroparticle and apparatus therefor |
| US20050079131A1 (en) | 2003-08-08 | 2005-04-14 | Lanza Gregory M. | Emulsion particles for imaging and therapy and methods of use thereof |
| US7419996B2 (en) | 2003-08-13 | 2008-09-02 | The University Of Houston | Parenteral and oral formulations of benzimidazoles |
| CH715855B1 (de) | 2003-08-28 | 2020-08-14 | Mibelle Ag | Zubereitung bestehend aus mindestens zwei Nanoemulsionen. |
| EP1510206A1 (en) | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| JP2006199589A (ja) | 2003-09-03 | 2006-08-03 | Ltt Bio-Pharma Co Ltd | 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 |
| US7160699B2 (en) | 2003-09-25 | 2007-01-09 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
| CA2543722C (en) | 2003-10-29 | 2011-01-04 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
| KR101045658B1 (ko) | 2003-11-17 | 2011-07-01 | 쎄데르마 | 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물 |
| NO20035681D0 (no) | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av lungekreft |
| US20050136024A1 (en) | 2003-12-22 | 2005-06-23 | Stockel Richard F. | Dermatological compositions |
| EP1547674A1 (en) | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Method for producing colloidal nanoparticles |
| US6974579B2 (en) | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
| FR2865131B1 (fr) | 2004-01-15 | 2007-08-24 | Gattefosse Ets Sa | Utilisation d'un extrait d'acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides |
| JP4966018B2 (ja) | 2004-01-23 | 2012-07-04 | カムルス エービー | 三元非ラメラ脂質組成物 |
| CN102764247B (zh) | 2004-01-30 | 2016-04-20 | 考里安国际公司 | 递送活性剂的快速溶解膜 |
| JP2007520555A (ja) | 2004-02-05 | 2007-07-26 | バクスター・インターナショナル・インコーポレイテッド | 自己安定化剤の使用により調製された分散剤 |
| CA2557261A1 (en) | 2004-02-23 | 2005-09-15 | The Texas A&M University System | Antioxidant compositions and methods of use thereof |
| DE102004009287A1 (de) | 2004-02-26 | 2005-09-15 | Institut Für Neue Materialien Gem. Gmbh | Amphiphile Nanopartikel |
| PT1729821E (pt) | 2004-03-03 | 2013-10-23 | Revance Therapeutics Inc | Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas |
| US20050214325A1 (en) | 2004-03-26 | 2005-09-29 | Vvii Newco 2003, Inc. | Compositions and methods to increase the effect of a neurotoxin treatment |
| KR101224262B1 (ko) | 2004-03-22 | 2013-01-21 | 셀진 코포레이션 | 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법 |
| DE102004016710B4 (de) | 2004-04-05 | 2020-11-19 | Greppmayr GmbH | Formulierung zur Fußpflege |
| EP1586336A1 (en) | 2004-04-06 | 2005-10-19 | JOHNSON & JOHNSON GmbH | Compositions containing copper salts and soy products |
| TW200603843A (en) | 2004-04-20 | 2006-02-01 | Technology Dev Company Ltd | Tissue enhancement implant and method |
| US20050249686A1 (en) | 2004-04-27 | 2005-11-10 | Francoise Pataut | Cosmetic composition free of water comprising fatty acid esters, petrolatum oil and non-ionic polymers |
| US7591806B2 (en) | 2004-05-18 | 2009-09-22 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
| US7228259B2 (en) | 2004-06-30 | 2007-06-05 | Lucent Technologies Inc. | Method and apparatus for structure-preserving reduced-order modeling |
| GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| WO2006019843A1 (en) | 2004-07-15 | 2006-02-23 | Nanobac Life Sciences | Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses |
| BRPI0513850A (pt) | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| KR100623013B1 (ko) | 2004-09-04 | 2006-09-19 | 김영대 | 나노에멀션, 그의 용도 및 제조방법 |
| CA2518650A1 (en) | 2004-09-10 | 2006-03-10 | Dimitrios Dimitrakoudis | Clostridium botulinum toxin formulation and method for reducing weight |
| JP2008513513A (ja) | 2004-09-21 | 2008-05-01 | アネシヴァ， インコーポレイテッド | ポリヌクレオチドの送達 |
| US20060073208A1 (en) | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| US9186345B2 (en) | 2004-10-12 | 2015-11-17 | Hakon Hakonarson | Method of treating skin diseases |
| US20060084353A1 (en) | 2004-10-18 | 2006-04-20 | Wong Tak K | Reversible ball having hyper-elastic properties |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| BRPI0404595A (pt) | 2004-10-26 | 2006-06-13 | Natura Cosmeticos Sa | nanoemulsão óleo-em-água, composição cosmética e produto cosmético compreendendo a mesma, processo para preparação da dita nanoemulsão |
| JP2008519784A (ja) | 2004-11-12 | 2008-06-12 | イデア アクチェンゲゼルシャフト | 皮膚状態の治療における拡張表面凝集体 |
| EP1848407A2 (en) | 2005-02-02 | 2007-10-31 | Mega Lifesciences Pvt. Ltd. | Oral pharmaceutical composition |
| US20080220021A1 (en) | 2005-02-14 | 2008-09-11 | Pankaj Modi | Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis |
| PL1853303T3 (pl) | 2005-02-14 | 2016-05-31 | Dpm Therapeutics Corp | Stabilizowane kompozycje do podawania miejscowego i sposoby ich otrzymywania |
| US9314431B2 (en) | 2005-02-14 | 2016-04-19 | Transdermal Corp | Solubilized benzoyl small molecule |
| US7727537B2 (en) | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
| US7838011B2 (en) | 2005-02-14 | 2010-11-23 | Pankaj Modi | Stabilized protein compositions for topical administration and methods of making same |
| CA2494473C (en) | 2005-02-14 | 2007-06-26 | Dpm Therapeutics Corp. | Stabilized protein compositions for topical administration and methods of making same |
| US8022179B2 (en) | 2005-03-03 | 2011-09-20 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| BRPI0608249A2 (pt) | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
| JP4444149B2 (ja) | 2005-03-30 | 2010-03-31 | 株式会社ナリス化粧品 | 超微細エマルジョンで構成される皮膚外用剤 |
| US8926991B2 (en) | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
| EP2248534A1 (en) | 2005-06-14 | 2010-11-10 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
| US8105611B2 (en) | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| CN103315954A (zh) | 2005-07-18 | 2013-09-25 | 麻萨诸塞州洛厄尔大学 | 制备与使用纳米乳剂的组合物和方法 |
| US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| WO2007015441A1 (ja) * | 2005-08-01 | 2007-02-08 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよび製剤 |
| CA2618974C (en) | 2005-08-09 | 2014-01-28 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
| US20090306198A1 (en) | 2005-09-16 | 2009-12-10 | Robert Nicolosi | Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner |
| US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| EP1933813A4 (en) | 2005-10-11 | 2013-02-27 | Univ Pittsburgh | SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER |
| DE102006046076A1 (de) | 2005-10-14 | 2007-04-19 | Henkel Kgaa | Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt |
| WO2007046102A2 (en) | 2005-10-19 | 2007-04-26 | Menni Menashe Zinger | Methods for the treatment of hyperhidrosis |
| BRPI0618510A2 (pt) | 2005-11-09 | 2011-09-06 | Hormos Medical Ltd | formulação medicamentosa lìquida ou semi-sólida |
| US20070148194A1 (en) | 2005-11-29 | 2007-06-28 | Amiji Mansoor M | Novel nanoemulsion formulations |
| TR201901443T4 (tr) | 2005-12-01 | 2019-02-21 | Univ Massachusetts Lowell | Botulinum nanoemülsiyonları. |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| US20070178121A1 (en) | 2006-01-27 | 2007-08-02 | Allergan, Inc. | Methods for enhancing skin treatments |
| JP2009527275A (ja) | 2006-02-17 | 2009-07-30 | ゾゲニクス インコーポレーティッド | 神経毒の送達のための方法およびシステム |
| US7939567B2 (en) | 2006-02-24 | 2011-05-10 | Blue Blood Biotech Corp. | Dextromethorphan-based method for treating acne |
| WO2007103555A2 (en) | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
| WO2008039245A2 (en) | 2006-04-27 | 2008-04-03 | Anterios, Inc. | Assessment of the effects of topical administration of chemodenervating pharmaceuticals |
| US20110135742A1 (en) | 2006-06-20 | 2011-06-09 | The Regents Of The University Of California | Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles |
| PL2494959T3 (pl) | 2006-07-05 | 2015-06-30 | Foamix Pharmaceuticals Ltd | Nośnik ze spienialnego kwasu dikarboksylowego oraz kompozycje farmaceutyczne z nośnikiem |
| WO2008016664A2 (en) | 2006-08-02 | 2008-02-07 | University Of Massachusetts Lowell | Compositions and methods for treating cancer with dacarbazine nanoemulsions |
| WO2008054362A2 (en) * | 2006-08-29 | 2008-05-08 | Nanomed Devices, Inc. | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
| CN103694349A (zh) | 2006-09-08 | 2014-04-02 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| US7445783B2 (en) | 2006-10-30 | 2008-11-04 | Cappellos, Inc. | Topical and transdermal treatments using urea formulations |
| US20080206155A1 (en) | 2006-11-14 | 2008-08-28 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
| CA2671133C (en) | 2006-12-01 | 2015-11-24 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
| EP2494958A1 (en) | 2006-12-01 | 2012-09-05 | Anterios, Inc. | Amphiphilic Entity Nanoparticles |
| US9364461B2 (en) | 2006-12-21 | 2016-06-14 | Santen Sas | Process for manufacturing ophthalmic oil-in-water emulsions |
| EP1938801A1 (en) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| US10016451B2 (en) | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
| EP2158467B1 (en) | 2007-06-20 | 2012-08-15 | Société de Technologie MICHELIN | Autolocation of all tires on a multi-axle vehicle |
| WO2009009417A2 (en) | 2007-07-06 | 2009-01-15 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
| EP2178549B1 (en) * | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
| US20120150023A1 (en) | 2007-08-06 | 2012-06-14 | Kaspar Roger L | Microneedle arrays for active agent delivery |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| BRPI0817664A2 (pt) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
| CN101911081A (zh) | 2007-11-05 | 2010-12-08 | 维斯塔实验室有限公司 | 用于临床试验的体系 |
| TWI661833B (zh) | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| KR20100135857A (ko) | 2008-03-28 | 2010-12-27 | 유니버시티 오브 매사추세츠 | 나노에멀젼의 제조를 위한 조성물 및 방법 |
| EP2293813A4 (en) | 2008-05-23 | 2012-07-11 | Univ Michigan | NANO EMULSION VACCINES |
| US20170361130A9 (en) | 2008-05-23 | 2017-12-21 | Pankaj Modi | Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation |
| AU2009293595A1 (en) | 2008-05-23 | 2010-03-25 | The Regents Of The University Of Michigan | Nanoemulsion adjuvants |
| KR20160130519A (ko) | 2008-06-26 | 2016-11-11 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| WO2010025128A1 (en) | 2008-08-25 | 2010-03-04 | Critical Biologics Corporation | Methods for reducing sample size of clinical trials |
| US20110206736A1 (en) | 2008-09-23 | 2011-08-25 | Thomas Jefferson University | Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same |
| ES2342754B1 (es) | 2008-10-03 | 2011-05-11 | Lipotec, S.A. | Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas, cuero cabelludo y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. |
| JP5879126B2 (ja) * | 2008-10-07 | 2016-03-08 | ジン・トゥオＪＩＮ Ｔｕｏ | 相転移ポリマーマイクロニードル |
| TW201023928A (en) * | 2008-11-12 | 2010-07-01 | Kythera Biopharmaceuticals Inc | Systems and methods for delivery of biologically active agents |
| US20100137357A1 (en) | 2008-11-26 | 2010-06-03 | Koleng John J | Compositions and methods for hyperhidrosis |
| HRP20180739T1 (hr) | 2008-12-31 | 2018-06-29 | Revance Therapeutics, Inc. | Injekcijske formulacije botulinskog toksina |
| EP2391342A2 (en) | 2009-01-28 | 2011-12-07 | Nanobio Corporation | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof |
| ES2349972B1 (es) | 2009-02-16 | 2011-11-24 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas. |
| WO2010123564A1 (en) | 2009-04-22 | 2010-10-28 | Agency For Science, Technology And Research | Emulsions for transdermal delivery |
| AU2010244428B2 (en) | 2009-05-06 | 2015-01-29 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| CA2766521C (en) * | 2009-06-25 | 2020-07-21 | Revance Therapeutics, Inc. | Albumin-free botulinum toxin formulations |
| EP2482838A4 (en) | 2009-09-30 | 2013-04-10 | Toxcure Inc | USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE |
| MX2012004406A (es) | 2009-10-21 | 2012-05-08 | Immunogen Inc | Nuevo regimen de dosificacion y metodo de tratamiento. |
| EP2529222A4 (en) | 2010-01-26 | 2013-10-09 | Ridge Diagnostics Inc | MULTIPLE BIOMARKER PANELS FOR STRATIFYING ILLNESS HEAVY GRADES AND MONITORING THE TREATMENT OF DEPRESSIONS |
| AU2011262309B2 (en) | 2010-06-01 | 2015-08-13 | Seqirus UK Limited | Concentration of influenza vaccine antigens without lyophilization |
| US20130078295A1 (en) | 2010-06-09 | 2013-03-28 | Lipotec S.A. | Skin antiaging treatment |
| US20110305735A1 (en) | 2010-06-09 | 2011-12-15 | Lipotec, S.A. | Skin antiaging treatment |
| US20120064136A1 (en) | 2010-09-10 | 2012-03-15 | Nanobio Corporation | Anti-aging and wrinkle treatment methods using nanoemulsion compositions |
| ES2390033B1 (es) | 2010-11-30 | 2013-10-31 | Lipotec S.A. | Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas. |
| US20120321571A1 (en) | 2011-01-24 | 2012-12-20 | Anterios, Inc. | Paraben compositions |
| WO2012103038A2 (en) | 2011-01-24 | 2012-08-02 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| WO2012103039A1 (en) | 2011-01-24 | 2012-08-02 | Anterios, Inc. | Surfactant compositions |
| EP2667860A1 (en) | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Compositions of empty nanoparticles and their use for treating dermatological conditions |
| US20120328549A1 (en) | 2011-01-24 | 2012-12-27 | Anterios, Inc. | Oil compositions |
| WO2012103035A1 (en) | 2011-01-24 | 2012-08-02 | Anterios, Inc. | Nanoparticle compositions |
| AU2012217858A1 (en) | 2011-02-15 | 2013-09-05 | Allergan, Inc. | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| BR112014001066A2 (pt) | 2011-07-20 | 2017-02-21 | Allergan Inc | toxinas botulínicas para uso em um método para tratamento de depósitos adiposos |
| EP2550975A1 (en) | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
| WO2013096026A1 (en) | 2011-12-21 | 2013-06-27 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
| CN104127859B (zh) | 2011-12-27 | 2015-08-19 | 中国药科大学 | 多肽在制备治疗或预防类风湿性关节炎药物中的应用 |
| MX2014011376A (es) | 2012-03-22 | 2014-10-14 | Revance Therapeutics Inc | Metodo de tratamiento de arrugas mediante agentes quimiodenervantes topicos. |
| EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
| WO2013156493A1 (en) | 2012-04-16 | 2013-10-24 | Lipotec S.A. | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
| WO2015020982A2 (en) | 2013-08-04 | 2015-02-12 | Aquavit Pharmaceuticals, Inc. | Direct application system and method for the delivery of bioactive compositions and formulations |
| MX370929B (es) * | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
| EP2792684A1 (en) | 2013-04-15 | 2014-10-22 | Lipotec, S.A. | Compounds useful in the treatment and/or care of the skin and their cosmetic or pharmaceutical compositions |
| CN103479627A (zh) | 2013-05-16 | 2014-01-01 | 武汉光谷百桥国际生物科技有限公司 | 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用 |
| AU2015252947B2 (en) | 2014-05-01 | 2020-07-09 | Anterios, Inc. | Demonstrable efficacy across or within patient populations |
| US9649266B2 (en) | 2014-05-01 | 2017-05-16 | Anterios, Inc. | Methods to treat, prevent, and improve skin conditions |
| AU2015337807B2 (en) | 2014-10-29 | 2017-05-04 | Samson Clinical Pty Ltd | Detection and treatment of excessive hair shedding |
| SG10202004337WA (en) | 2015-10-29 | 2020-06-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
| US20170209553A1 (en) | 2016-01-22 | 2017-07-27 | Transderm, Inc. | Delivery of botulinum with microneedle arrays |
| US11311496B2 (en) * | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| WO2020056191A1 (en) | 2018-09-13 | 2020-03-19 | Eirion Therapeutics, Inc. | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors |
| EP3849539A1 (en) | 2018-09-13 | 2021-07-21 | Eirion Therapeutics, Inc. | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor |
| AU2019391791A1 (en) | 2018-12-03 | 2021-06-03 | Eirion Therapeutics, Inc. | Improved delivery of large agents |
| JP2022533113A (ja) | 2019-05-14 | 2022-07-21 | エイリオン セラピューティクス， インコーポレイテッド | ピーク効果の遅延および／または応答持続時間の延長 |
-
2017
- 2017-09-25 US US16/462,485 patent/US11311496B2/en active Active
- 2017-09-25 BR BR112019010131A patent/BR112019010131A2/pt active Search and Examination
- 2017-09-25 JP JP2019547574A patent/JP2019535829A/ja not_active Withdrawn
- 2017-09-25 CN CN202311762526.9A patent/CN117731591A/zh active Pending
- 2017-09-25 CN CN201780083993.5A patent/CN110198703A/zh active Pending
- 2017-09-25 EP EP17780963.9A patent/EP3541358A1/en active Pending
- 2017-09-25 WO PCT/US2017/053333 patent/WO2018093465A1/en not_active Ceased
- 2017-09-25 AU AU2017360346A patent/AU2017360346B2/en active Active
- 2017-09-25 KR KR1020197017767A patent/KR102487144B1/ko active Active
- 2017-09-25 MX MX2019005833A patent/MX2019005833A/es unknown
- 2017-09-25 CA CA3044219A patent/CA3044219A1/en active Pending
-
2019
- 2019-05-17 MX MX2023006706A patent/MX2023006706A/es unknown
- 2019-05-19 IL IL266733A patent/IL266733A/en unknown
- 2019-05-31 ZA ZA2019/03467A patent/ZA201903467B/en unknown
-
2022
- 2022-03-16 US US17/696,509 patent/US20220218623A1/en active Pending
- 2022-08-25 JP JP2022134512A patent/JP2022164750A/ja active Pending
-
2024
- 2024-09-02 JP JP2024150911A patent/JP2024167362A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190343773A1 (en) | 2019-11-14 |
| KR102487144B1 (ko) | 2023-01-12 |
| US11311496B2 (en) | 2022-04-26 |
| US20220218623A1 (en) | 2022-07-14 |
| AU2017360346A1 (en) | 2019-06-13 |
| WO2018093465A1 (en) | 2018-05-24 |
| EP3541358A1 (en) | 2019-09-25 |
| JP2019535829A (ja) | 2019-12-12 |
| JP2022164750A (ja) | 2022-10-27 |
| CN117731591A (zh) | 2024-03-22 |
| CN110198703A (zh) | 2019-09-03 |
| MX2023006706A (es) | 2023-06-20 |
| MX2019005833A (es) | 2019-10-30 |
| AU2017360346B2 (en) | 2023-11-23 |
| IL266733A (en) | 2019-07-31 |
| KR20190087517A (ko) | 2019-07-24 |
| BR112019010131A2 (pt) | 2019-10-08 |
| ZA201903467B (en) | 2022-12-21 |
| JP2024167362A (ja) | 2024-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220218623A1 (en) | Transdermal delivery of large agents | |
| AU2025226856A1 (en) | Improved Delivery of Large Agents | |
| JP6841736B2 (ja) | ボツリヌス菌ナノエマルジョン | |
| KR20180077202A (ko) | 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법 | |
| JP2025118791A (ja) | ピーク効果の遅延および／または応答持続時間の延長 | |
| JP2014001211A (ja) | Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法 | |
| HK40060152A (en) | Improved delivery of large agents | |
| HK40070640A (en) | Delaying peak effect and/or extending duration of response | |
| HK40013656A (en) | Transdermal delivery of large agents | |
| BR122025013906A2 (pt) | Composição de agentes grandes, emplastro, kit e seus usos transdérmicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| EEER | Examination request |
Effective date: 20220921 |
|
| EEER | Examination request |
Effective date: 20220921 |
|
| EEER | Examination request |
Effective date: 20220921 |